Orthocell Ltd (ASX: OCC) shares are in focus today after its share price tumbled 7% to start the week of trading on Monday.
This came following the company’s Quarterly Activity Report.
Orthocell is a regenerative medicine company. The company is engaged in the development and commercialisation of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry.
What did Orthocell report?
The company released its Quarterly Report for the quarter ended 31 March 2026 yesterday.
It reported:
- Year-to-date (Q1âQ3 FY26) revenue of $9.4 million represents a 45% increase on the prior corresponding period
- March quarter revenue in line with the prior quarter, with U.S. sales reaching $300k
- Total revenue of $3.2m.Â
Speaking on the result, Orthocell CEO and MD, Paul Anderson, said:
This quarter reflects continued strong progress in the commercialisation of Remplir, particularly in the United States, where we are seeing growing surgeon adoption and increasing revenue contribution.
The consistency of our revenue performance and the growth in key commercial metrics, including hospital uptake, surgeon utilisation and distributor expansion, is particularly encouraging. Notably, the acceleration in U.S. revenue in March provides early evidence of a potential inflection point as these commercial efforts begin to scale.
Investors were seemingly left wanting more, as investors largely exited their positions in Orthocel shares on Monday.
What did Bell Potter have to say?
Following the result, the team at Bell Potter released updated guidance on the company.
The broker said the March quarter total revenue of $3.2m was flat QoQ (+45% pcp), which
appears broadly consistent with softer seasonal conditions typically seen in calendar Q1.
It also pointed to some lag on repeat ordering as first use surgeons evaluate product performance in their own case.
The quarter also marked the first meaningful US revenue contribution, with $300k of Remplir revenue, including $170k generated in March alone.
Speculative buy rating for Orthocell shares
Orthocell shares closed yesterday at $0.955 per shares after a 7.7% drop.
However, Bell Potter maintained its speculative buy rating, while also increasing its price target to $1.240 (previously A$1.150).
From yesterday’s closing price, this updated target indicates an upside of approximately 30%.
We maintain our BUY (spec.) recommendation and raise our valuation to $1.24. While the military hospital access win represents a meaningful de-risking event, we expect uptake across these channels to take time to establish, with the greater earnings contribution likely to emerge over later years.
The post Are Orthocell shares a buy after crashing 7% yesterday? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Orthocell Limited right now?
Before you buy Orthocell Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Orthocell Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Orthocell caps 26% surge this week with first US Military Surgery
- Orthocell shares soar 22% on landmark US breakthrough
Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.